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A B S T R A C T
The importance of angiogenesis in pancreatic ductal adenocarcinoma (PDAC) and its therapeutic poten-
tial have been explored in both pre-clinical and clinical studies. Human PDACs overexpress a number of
angiogenic factors and their cognate high-aﬃnity receptors, and anti-angiogenic agents reduce tumor
volume, metastasis, and microvessel density (MVD), and improve survival in subcutaneous and ortho-
topic pre-clinical models. Nonetheless, clinical trials using anti-angiogenic therapy have been
overwhelmingly unsuccessful. This review will focus on these pre-clinical and clinical studies, the po-
tential reasons for failure in the clinical setting, and ways these shortcomings could be addressed in future
investigations of angiogenic mechanisms in PDAC.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Pancreatic ductal adenocarcinoma (PDAC), which comprises >85%
of pancreatic cancers, is the 4th leading cause of cancer death in
the United States with a 1- and 5-year relative survival of 28% and
7%, respectively [1–3]. These statistics are largely due to advanced
stage at clinical presentation, the high frequency of major driver mu-
tations, marked resistance to chemotherapy and radiation, and
extensive desmoplasia that impedes drug delivery [4–8]. Because
advances in screening, prevention, and treatment are limited com-
pared to other cancers, PDAC is now projected to surpass breast,
prostate, and colorectal cancers to become the second leading cause
of cancer death by 2030 [9].
At presentation, only 15–20% of patients are eligible for surgi-
cal resection, the only chance for cure [1–3]. Even then, outcomes
are poor, with a 5 year survival between 20 and 25% post-resection,
since most of these patients develop disease recurrence [10]. There-
fore, chemotherapy is recommended as adjuvant treatment for those
undergoing surgical resection and is the mainstay of treatment for
patients with locally advanced or metastatic disease [2]. The current
standard of care for patients with metastatic disease includes
gemcitabine plus nab-paclitaxel or ﬂuorouracil plus leucovorin,
irinotecan, and oxaliplatin (FOLFIRINOX) [2,11].
Angiogenesis
Blood vessel growth throughout adult life is primarily achieved
via angiogenesis [12–18]. However, the adult vasculature is mostly
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quiescent as only 0.01% of the endothelium undergoes cell divi-
sion at any time [12,13,15,17,18]. Examples of physiological
angiogenesis in the adult include wound healing, tissues undergo-
ing growth, exercise induced angiogenesis in heart and skeletal
muscle, the hair cycle, skeletal growth, and female reproductive pro-
cesses. Pathological examples include intraocular neovascular
disorders, infantile hemangiomas, immunogenic rheumatoid ar-
thritis, psoriasis, and tumorigenesis [12,13,16–20].
Through the use of models like the mouse retina, which becomes
vascularized postnatally, we now understandmany of the key players
and processes involved in physiological angiogenesis [21]. In general,
activation of endothelial cells by pro-angiogenicmolecules leads to the
detachment of pericytes from the endothelium and remodeling of the
basement membrane and cell-to-cell junctions (Fig. 1) [22]. The best
known pro-angiogenic molecule is vascular endothelial growth factor
A (gene: VEGFA) (VEGF-A). VEGF-Abinds to vascular endothelial growth
factor receptor 2 (gene: KDR) (VEGFR-2) on endothelial cells, and its
signaling is enhanced by the neuropilin-1 (NRP1) co-receptor, which
facilitates complex internalization (Fig. 1) [22]. Downstream signal-
ing results in increased expression of theNotch ligand delta-like protein
4 (DLL4), which binds to Notch receptors on neighboring endothelial
cells (Fig. 1) [22]. This releases the notch intracellular domain (NICD)
in these cells, which down-regulates VEGFR-2 and NRP1, and up-
regulates vascular endothelial growth factor receptor 1 (gene: FLT1)
(VEGFR-1), a decoy receptor for VEGF-A (Fig. 1) [22].
The goal of this process is to isolate one cell that will migrate
toward the pro-angiogenic gradient (called the tip cell) while
de-sensitizing neighboring cells to the same signal. It is believed
that DLL4 and Notch signaling are balanced in the quiescent vas-
culature, and that tip cells will offset the balance in response to pro-
angiogenic signals [14]. The cells adjacent to the tip cell are called
stalk cells, and they proliferate behind the tip cell to elongate the
sprout and form a lumen (Fig. 1) [22]. Once two tip cells on differ-
ent sprouts meet, they will anastomose to form a perfused branch
(Fig. 1) [22]. Basement membrane then forms, and pericytes are re-
cruited to cover the vessel (Fig. 1) [22]. The process is dynamic in
that endothelial cells will compete for the tip position with differ-
ent cells displaying the phenotype over time.
Tumor angiogenesis
Whereasphysiological angiogenesis is tightly controlledandcomes
to a resolution, pathological angiogenesis is abnormal and does not
resolve [13,16,17,20,21]. Because cells need nutrients and oxygen
fromnearby capillaries to function and survive, early tumor growth
is often restricted to a volume of only a few cubic millimeters until
it is able to switch to an angiogenic phenotype [13,16,17,19,20,23,24].
Activation of angiogenesis occurs when pro-angiogenic molecules
predominate over anti-angiogenic molecules, whereas inactiva-
tion occurswhen the anti-angiogenicmolecules dominate [12,13,25].
Fig. 1. PDAC angiogenesis. In PDAC, pancreatic cancer cells (PCCs) proliferate within a desmoplastic stroma that consists of both cellular components such as cancer associ-
ated ﬁbroblasts (CAFs), immune cells (Is), and endothelial cells (ECs) as well as extracellular matrix (ECM) components like soluble growth factors, cytokines, collagens, ﬁbronectin,
laminin, glycoproteins, and proteoglycans. Up-regulation of hypoxia inducible factor 1, alpha subunit (gene: HIF1A) (HIF-1α) and the pro-angiogenic molecule VEGF-A within
PCCs results in secretion of VEGF-A molecules into the tumor microenvironment. When VEGF-A signals through VEGFR-2 and its NRP1 co-receptor on endothelial cells, down-
stream signaling results in increased expression of DLL4. DLL4will bind to Notch receptors on neighboring cells, subsequently releasing NICD, which then down-regulates VEGFR-2
and NRP1 expression and up-regulates expression of the VEGFR-1 decoy receptor. This favors migration of a tip cell toward the VEGF-A gradient while the neighboring stalk
cells become de-sensitized to the signal. In the quiescent vasculature, DLL4 and Notch signaling are balanced. Small molecule inhibitors of angiogenesis, such as Axitinib, Sunitinib,
Sorafenib, and Vatalanib primarily act on the vascular endothelial growth factor receptor complexes (VEGFR-1, VEGFR-2, and Vascular endothelial growth factor receptor 3 (gene:
FLT4) (VEGFR-3)), while recombinant protein inhibitors of angiogenesis like Bevacizumab, Elpamotide, and Ziv-Aﬂibercept act on vascular endothelial growth factor ligands
like VEGF-A, vascular endothelial growth factor B (gene: VEGFB) (VEGF-B), and/or placenta growth factor (gene: PGF) (PlGF).
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In tumorigenesis, the observed activation from a quiescent state is
often described as an “angiogenic switch” [12,13,25].
The vessels formed during tumor angiogenesis are tortuous or dis-
organized, immature, and convolutedwith excessive vessel branching
lacking pericyte coverage rendering them fragile and leakywith bleed-
ing and exudation of plasma proteins [15–18,21,22,24,26]. The
distributionof newvessels in the tumor is alsoheterogeneouswith some
areas demonstrating intense neovascularization [15,19,20,22,26]. The
vessels are often functionally defectivewith lowbloodﬂowand reduced
oxygen delivery due to high interstitial pressure [15,18,22,26]. The re-
sulting hypoxic environment exacerbates the pathological condition by
further up-regulating pro-angiogenicmolecules [15,22,26].While one
might assume that neovascularizationwould improve delivery of che-
motherapeutic agents to the tumor, the poor perfusion and compression
of the vascular supply actually impedes drug delivery [15,16,18,20,22].
Therefore, in addition to inhibiting angiogenesis and causing
vessel regression, anti-angiogenic agents can enhance the effects of si-
multaneously administered chemotherapeutic drugs bynormalizing the
remaining vasculature [15,16,18,20–22,26].
PDAC is hypovascular
Though the previously discussed concepts are generalities common
tomanycancers,wenowspeciﬁcally consider concepts relevant toPDAC.
Using the KrasLSL-G12D/+, Trp53LSL-R172H/+, Pdx-1-Cre (KPC) PDAC mouse
model,whichhasoncogenicKirsten rat sarcomaviral oncogenehomolog
(Kras) and mutated transformation related protein 53 (Trp53) in the
pancreas due to Cre-mediated recombination, Olive et al. showed that
KPC tumors are poorly vascularized, poorly perfused, and have im-
paired drug delivery when compared to KPC transplant models or
normal mouse pancreas [27]. Likewise, using both KrasLSL-G12D/+, Pdx-
1-Cre (KC)mice,which have oncogenic Kras in the pancreas due to Cre-
mediated recombination, andKPCmice, Provenzano et al. reported that
in addition to having reduced vascularity, KC and KPC tumors have a
paucity of large diameter (>10 um) vessels when compared to normal
mouse pancreas [28]. This is likely due to vascular collapse caused by
the presence of very high interstitial ﬂuid pressures in these tumors,
in the range of 75–130mmHg, compared to 8–13mmHg in normal
mouse pancreas [28]. This observation also offers an explanation for
the poor perfusion and drug delivery observed by Olive et al. [27].
Human PDAC sampleswere also shown to be poorly vascularized com-
pared to normal human pancreas or adjacent normal human pancreas,
and to have fewer large diameter vessels compared to adjacent normal
human pancreas [27,28].
Because PDAC is inherently hypovascular, it might be assumed
that this cancer either does not demonstrate signiﬁcant angiogen-
esis or is not likely to beneﬁt from anti-angiogenic agents. However,
both concepts have been disproven in other cancers [29]. All tumor
types need suﬃcient levels of nutrients and oxygen and are growth
limited unless they are able to induce angiogenesis. This is also true
of hypoxic tumors, which likely have increased requirements to drain
away toxic by-products released by cancer cells. Instead of mea-
suring angiogenesis, microvessel density (MVD) rather reﬂects the
metabolic burden of the supported tumor cells [29]. In fact, because
the oxygen consumption rate is often lower in tumors compared
to the corresponding normal tissue, it is not uncommon for tumors
to have lower MVDs as we see in PDAC [29]. This is also the case
for renal cell carcinoma, a cancer known clinically to respond to anti-
angiogenic therapy [29]. Both poorly and highly vascularized cancers
have been shown to respond to anti-angiogenic therapy [29].
Correlation of VEGF-A expression or microvessel density with
health outcomes in PDAC
VEGF-A, a potent inducer of angiogenesis, was ﬁrst discovered
as a secreted protein that can enhance vascular permeability [12].
Many different isoforms exist, and their different binding aﬃnities
for heparan sulfate proteogylycans (HSPGs) function to create a gra-
dient for guiding vessels during vascular development [16]. In recent
years, more insight into the alternative splicing and translation of
the gene has revealed that anti-angiogenic forms and a transla-
tional read through can also be produced [30,31].
Using immunohistochemistry (IHC), several groups found that
between 60 and 65% of human PDAC samples have a substantial
amount of VEGF-A immunoreactivity [32–34]. In terms of gene ex-
pression, Ikeda et al. found that 27/40 (67.5%) human PDAC samples
overexpressVEGFAcompared to a colon cancer cell line,while Itakura
et al. found a 5.2 fold increase in VEGFA expression in human PDAC
samples (n = 7) compared to normal humanpancreas samples (n = 4)
[32,34]. More recently, by RNA-Sequencing (RNA-Seq), The Cancer
GenomeAtlas (TCGA)dataset shows that only8outof 178 (4%)human
PDAC samples overexpress VEGFA, suggesting that this growth factor
may not be as important in PDAC as was ﬁrst surmised [8,35,36].
MVD has not been shown to be an accurate measure of angio-
genesis in other cancers [29]; nonetheless, three [32–34] of four [37]
studies of human PDAC samples have shown an association between
VEGFA mRNA or VEGF-A protein (IHC) expression and the amount
of vascularity seen in the tumor. Patients with high levels of VEGFA
mRNA or VEGF-A protein (IHC) also had increased liver metastasis
[33], larger tumors [34], enhanced local spread [34], and de-
creased survival in two [32,33] out of four [34,37] studies. Lastly,
one [32] out of two [37] studies reported that increased vascular-
ity was associated with decreased patient survival.
Pre-clinical studies targeting VEGF signaling in PDAC
Many studies have examined the potential role of targeting VEGF
signaling using subcutaneous or orthotopic nude mouse models of
human PDAC. Injection of human PDAC cells expressing an anti-
sense VEGFA into the ﬂanks of nude mice led to an 80% reduction
in tumor size compared to controls [38]. When diphtheria toxin,
which inhibits protein synthesis in target cells, was fused with
VEGF-A to target it to the vasculature in orthotopic nude mouse
models of human PDAC, it led to reduced tumor volume, tumor
spread, andMVD, and improvement in survival in 1 of 2models [39].
Injection of adenovirus vectors encoding the soluble form of the
decoy receptor VEGFR-1 into subcutaneous tumor xenografts of
human PDAC in SCID mice also resulted in reduced tumor growth
and MVD [40]. Additionally, injection of adenovirus vectors encod-
ing soluble VEGFR-1 or soluble VEGFR-1 plus a soluble ﬁbroblast
growth factor receptor 1 (gene: FGFR1) (FGFR-1) into subcutane-
ous tumor xenografts of human PDAC in nude mice resulted in
reduced tumor growth [41].
The tyrosine kinase inhibitor PTK 787/ZK222584 (vatalanib)
targets VEGF receptors, the platelet-derived growth factor recep-
tors (PDGFRs), the mast/stem cell growth factor receptor Kit (gene:
KIT) (SCFR), and macrophage colony-stimulating factor 1 receptor
(CSF1R). Use of this compound in an orthotopic nude mouse model
of human PDAC led to reduced tumor volume and MVD, and in-
creased survival [42]. Moreover, use of VEGF-Trap (ziv-aﬂibercept),
which is a recombinant fusion protein of the extracellular por-
tions of VEGFR-1 and VEGFR-2 and the Fc fragment of human
immunoglobulin IgG1, resulted in reduced tumor growth and MVD
in subcutaneous tumor xenografts of human PDAC and reduced
tumor growth and metastasis in an orthotopic nude mouse model
of human PDAC [43]. These promising results provide support for
the testing of anti-VEGF agents in human PDAC clinical trials.
Clinical studies in PDAC
To date, many phase II and phase III human PDAC clinical trials
using different anti-angiogenic agents have been completed. Several
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of these involved bevacizumab, an anti-VEGF-A monoclonal anti-
body, that has already been Food and Drug Administration (FDA)
approved for the treatment of several other cancer types, includ-
ing metastatic renal cell carcinoma in combination with interferon
alpha, glioblastoma as a second-line therapy, or in combination with
chemotherapy in the following cancers: platinum-resistant recur-
rent epithelial ovarian, fallopian tube, or primary peritoneal cancer;
persistent, recurrent, or metastatic cervical cancer; metastatic
colorectal cancer; or non-small cell lung cancer.
An initial Phase II trial of bevacizumab plus gemcitabine in un-
treated advanced PDAC patients showed a 21% objective response
rate (ORR), a 6-month survival rate of 77%, and a median survival
of 8.8 months (Table 1) [44]. Because these were favorable numbers
compared to the pivotal trial for gemcitabine approval [45], which
observed an ORR of 5%, a 6-month survival rate of 46%, and amedian
survival of 5.7 months, several other Phase II and Phase III studies
were launched.
Several Phase II trials added bevacizumab to any existing regimen
that had previously shown any sort of modest activity in PDAC. These
regimens included: cisplatin and gemcitabine [46]; capecitabine and
gemcitabine [47]; capecitabine, radiation, and gemcitabine [48];
oxaliplatin and gemcitabine [49]; gemcitabine and radiation [50,52],
and docetaxel [51] (Table 1). However, results from the Phase III trial
directly comparing bevacizumab plus gemcitabine to placebo plus
gemcitabine in advanced PDAC patients showed that the addition
of bevacizumab does not result in an improvement in overall sur-
vival (OS) or progression free survival (PFS) or differences in the ORR
(Table 2) [61].
The difference between the Phase II and Phase III results was sug-
gested to be due to the Phase II trial recruiting a more ﬁt population
[61]. Because such disparities are common in trials of PDAC, it was
also suggested that the use of a single-arm Phase II trial is not ideal
[61]. The majority of Phase II trials with other regimens were single-
arm trials, and thus, most of them also concluded that the addition
of bevacizumab produced questionable beneﬁt.
In addition to VEGF-A, epidermal growth factor receptor (EGFR)
and its ligands are commonly overexpressed in human PDAC, and
high expression levels are also associated with worse outcomes
[66–69]. The addition of cetuximab, a monocloncal antibody tar-
geting EGFR, to gemcitabine has not led to improvements in ORRs,
PFS, or OS [70], but the addition of erlotinib, a small molecule in-
hibitor of EGFR, to gemcitabine has been shown to provide a
statistically signiﬁcant improvement in survival [71]. However, the
clinical relevance of this result is often questioned since the median
gain in survival is only 10 days [71].
There is also evidence for EGFR’s role in angiogenesis and si-
multaneous inhibition of EGFR and VEGFR-2 has been shown to be
synergistic [66,68,72–74]. Therefore, several regimens combining
cetuximab or erlotinib with bevacizumab have been tried with
limited success (Table 3) [75–77]. A Phase III trial comparing
bevacizumab plus erlotinib plus gemcitabine to placebo plus erlotinib
plus gemcitabine in metastatic PDAC patients did not show beneﬁt
in OS, but it did show a statistically signiﬁcant one month improve-
ment in the median PFS (Table 2) [60]. Therefore, there is some
rationale for using this drug combination inmetastatic PDAC patients.
Additional anti-angiogenic agents that have been tried in human
PDAC include axitinib, sunitinib, sorafenib, vatalanib, ziv-aﬂibercept,
and elpamotide. The Phase II or III trial comparing axitinib, a VEGFR
tyrosine kinase inhibitor, plus gemcitabine to gemcitabine alone did
not provide a signiﬁcant improvement in overall or PFS (Tables 1
and 2) [53,62].
Sunitinib is a smallmolecule tyrosine kinase inhibitor of VEGFRs,
PDGFRs, and SCFR. Though a Phase III study has not been done, this
molecule has been tested in the metastatic setting as either a
second-line therapy [54] or amaintenance therapy in patients who
did not progress after ﬁrst-line chemotherapy [55]. Interestingly, in
thesepatient groups, thedrugdidnotdowell as a second-line therapy
(Table 1), but produced a statistically signiﬁcant improvement in
PFS compared to observation alone in the maintenance setting
(hazard ratio [HR] 0.51 [95% conﬁdence interval (CI): 0.29–0.89],
p-value < 0.01) [55]. Because the duration of ﬁrst-line chemother-
apy is often debated due to its cumulative toxicity and unproven
eﬃcacy, sunitinibmayoffer an advantage in themaintenance setting.
Similarly, sorafenib is a small molecule tyrosine kinase inhibi-
tor of serine/threonine-protein kinase B-raf (BRAF), VEGFRs, and
platelet-derived growth factor receptor beta (PDGFRB) that has been
tested in many different settings without beneﬁt (Tables 1 and 3)
[56–58,78]. These observations were conﬁrmed in a Phase III trial
that observed no improvement in overall or PFS upon the addi-
tion of sorafenib to gemcitabine in the treatment of advanced PDAC
patients (Table 2) [63].
Vatalanib is also a multi-kinase inhibitor targeting VEGFRs,
PDGFRs, SCFR, and CSF1R. In a Phase II trial, it was used as a second-
line therapy in advanced PDAC patients and produced a favorable
6 month survival rate of 29% compared to historic controls (Table 1)
[59]. However, it was only a single-arm trial, and with the failure
of several other similar receptor tyrosine kinase inhibitors, it remains
to be seen whether this drug will pan out.
Ziv-aﬂibercept, a recombinant fusion protein consisting of the
extracellular portions of VEGFR-1 and VEGFR-2 and the Fc frag-
ment of human immunoglobulin IgG1, is another drug that targets
the VEGF pathway by trapping VEGF-A, VEGF-B, and PlGF. This drug
yielded negative results in a Phase III trial compared to gemcitabine
alone (Table 2) [64].
Elpamotide, a VEGFR-2 peptide, is a vaccine immunotherapy that
can induce a cellular immune response against VEGFR-2 express-
ing endothelial cells [65,79]. In a Phase II/III trial (Table 2) of locally
advanced or metastatic pancreatic cancer patients, there were no
improvements in overall or PFS compared to gemcitabine alone, but
a subgroup with severe injection site reactions tended to do better,
suggesting that this may be a sign of immune response to the vaccine
[65].
Thus, targeting the VEGF pathway alone is not an eﬃcacious route
in PDAC. Even targeting multiple players in the neoplastic process,
like EGFR or other receptor tyrosine kinases, produced marginal
beneﬁt, with only two trials showing an improvement in PFS, but
not OS [55,60].
Reasons for failure
The overwhelming failure of anti-angiogenic agents in the clinic
leads us to speculate on the reasons for the failure. Over the last
20 years, efforts in targeting angiogenesis in cancer have focused
almost entirely on the pro-angiogenic molecule VEGF-A, and there
are now several FDA approved drugs for various cancers
[15,18,21,22,26,80]. In reality, despite very convincing pre-clinical
data, some cancers are resistant to such therapy or develop resis-
tance over time [15,18,21,22,25,26,80]. This suggests that other
angiogenic pathways that we have yet to address are involved.
Indeed, other pro-angiogenic molecules include ﬁbroblast growth
factors (FGFs), platelet-derived growth factors (PDGFs), angiopoietins
(ANGPTs), transforming growth factor beta (gene: TGFB1) (TGF-β),
and cytokines like interleukin-8 (gene: CXCL8) (IL-8) [73,81]. Thus,
to block angiogenesis effectively, we need to target multiple mol-
ecules simultaneously.
Because many pro-angiogenic growth factors such as VEGF-A,
FGF2, PDGFs, TGF-β, and heregulin (gene: NRG1) (HRG) bind to
HSPGs to facilitate their signaling, another targetable common de-
nominator would be these proteoglycans [73,81]. The validity of
this strategy has been shown with KrasLSL-G12D/+, Cdkn2aLoxP/LoxP,
Pdx-1-Cre (KIC) mice that were null for glypican-1 (Gpc1), one of
the HSPGs. KIC mice have oncogenic Kras and deleted
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Table 1
Phase II clinical trials using anti-angiogenic agents in PDAC.
Ref Phase Group Drug Experimental arm Active comparator arm Hazard ratio
Kindler et al. [44] II Advanced Bevacizumab (anti-VEGF-A
monoclonal antibody)
• Bevacizumab + gemcitabine
– ORR: 21% (11–35%)
– 6 m survival: 77% (63–86%)
– OS: 8.8 m (7.4–9.7 m)
– PFS: 5.4 m (3.7–6.2 m)
NA NA
Ko et al. [46] II Metastatic Bevacizumab (anti-VEGF-A
monoclonal antibody)
• Bevacizumab + cisplatin + gemcitabine
– ORR: 19.2%
– OS: 8.2 m (6.9–11.1 m)
– TTP: 6.6 m (4.6–8.8 m)
NA NA
Javle et al. [47] II Advanced Bevacizumab (anti-VEGF-A
monoclonal antibody)
• Bevacizumab + capecitabine + gemcitabine
– ORR: 22%
– OS: 9.8 m (8.3–11.9 m)
– PFS: 5.8 m (4.2–7.8 m)
NA NA
Crane et al. [48] II Locally advanced
(unresectable)
Bevacizumab (anti-VEGF-A
monoclonal antibody)
• Bevacizumab + capecitabine + radiation
followed by gemcitabine + bevacizumab
– ORR: 26%
– OS: 11.9 m (9.9–14 m)
– PFS: 8.6 m (6.9–10.5 m)
NA NA
Fogelman et al. [49] II Advanced Bevacizumab (anti-VEGF-A
monoclonal antibody)
• Bevacizumab + oxaliplatin + gemcitabine
– ORR: 36%
– 6 m survival: 74%
– OS: 11.9 m
– PFS: 4.9 m
NA NA
Small et al. [50] II Localized Bevacizumab (anti-VEGF-A
monoclonal antibody)
• Bevacizumab + radiation + gemcitabine, then
surgery or bevacizumab + gemcitabine
– ORR: 11% (4–24%)
– 6 m survival: 86%
– OS: 11.8 m
– PFS: 9.9 m
NA NA
Astsaturov et al. [51] II Metastatic Bevacizumab (anti-VEGF-A
monoclonal antibody)
• Bevacizumab
– ORR: 0%
– OS: 165 d
– PFS: 43 d
• Bevacizumab + docetaxel
– ORR: 0%
– OS: 125 d
– PFS: 48 d
NA
Van Buren II et al. [52] II Localized (potentially
resectable)
Bevacizumab (anti-VEGF-A
monoclonal antibody)
• Neoadjuvant bevacizumab + gemcitabine,
then radiation
– OS: 16.8 m (14.9–21.3 m)
– PFS: 6.6 m (4.9–12.4 m)
NA NA
(continued on next page)
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Table 1 (continued)
Ref Phase Group Drug Experimental arm Active comparator arm Hazard ratio
Spano et al. [53] II Advanced Axitinib (SMI of VEGFRs) • Axitinib + gemcitabine
– ORR: 7% (2.4–16.1%)
– OS: 6.9 m (5.3–10.1 m)
– PFS: 4.2 m (3.6–10.2 m)
• Gemcitabine
– ORR: 3% (0.1–15.3%)
– OS: 5.6 (3.9–8.8) m
– PFS: 3.7 (2.2–6.7) m
• OS HR 0.71 (0.44–1.13)
• PFS HR 0.79 (0.43–1.45)
O’Reilly et al. [54] II Metastatic (second-line
therapy)
Sunitinib (SMI of VEGFRs, PDGFRs,
SCFR)
• Sunitinib
– ORR: 1.4%
– OS: 3.68 m (3.06–4.24 m)
– PFS: 1.31 m (1.25–1.38 m)
NA NA
Reni et al. [55] II Metastatic (maintenance
therapy)
Sunitinib (SMI of VEGFRs, PDGFRs,
SCFR)
• Sunitinib
– ORR: 0%
– OS: 10.6 m (6.2–18.9 m)
– PFS: 3.2 m
• Observation
– ORR: 0%
– OS: 9.2 m (5.9–16.3 m)
– PFS: 2 m
• OS HR 0.11 (0.4–1.26)
• PFS HR 0.51* (0.29–0.89)
El-Khoueiry et al. [56] II Metastatic Sorafenib (SMI of BRAF, VEGFR-2,
PDGFRB)
• Sorafenib
– 6 m survival: 43%
– OS: 4.3 m (3.3–8.3 m)
– PFS: 2.3 m (1.2–5.7 m)
• Sorafenib + gemcitabine
– 6 m survival: 53%
– OS: 6.5 m (5.5–8 m)
– PFS: 2.9 m (2.1–4.3 m)
NA
Kindler et al. [57] II Advanced Sorafenib (SMI of BRAF, VEGFR-2,
PDGFRB)
• Sorafenib + gemcitabine
– ORR: 0%
– 6 m survival: 23% (6–47%)
– OS: 4 m (3.4–5.9 m)
– PFS: 3.2 m (1.6–3.6 m)
NA NA
Cascinu et al. [58] II Advanced Sorafenib (SMI of BRAF, VEGFR-2,
PDGFRB)
• Sorafenib + cisplatin + gemcitabine
– ORR: 3.4%
– OS: 7.5 m (5.6–9.7 m)
– PFS: 4.3 m (2.7–6.5 m)
• Cisplatin + gemcitabine
– ORR: 3.6%
– OS: 8.3 m (6.2–8.7 m)
– PFS: 4.5 m (2.5–5.2 m)
• OS HR 0.95 (0.62–1.48)
• PFS HR 0.92 (0.62–1.35)
Dragovich et al. [59] II Advanced (second-line
therapy)
Vatalanib (SMI of VEGFRs, PDGFRs,
SCFR, CSF1R)
• Vatalanib
– ORR: 3.1%
– 6 m survival: 29% (18–41%)
– PFS: 2 m
NA NA
Ref, reference; SMI, small molecule inhibitor; ORR, objective response rate; OS, overall survival; PFS, progression free survival; TTP, time to progression; HR, hazard ratio; m, month(s); d, days(s); VEGF-A, vascular endothelial
growth factor A (gene: VEGFA); VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; SCFR, mast/stem cell growth factor receptor Kit (gene: KIT); BRAF, serine/threonine-protein
kinase B-raf; VEGFR-2, vascular endothelial growth factor receptor 2 (gene: KDR); PDGFRB, platelet-derived growth factor receptor beta; CSF1R, macrophage colony-stimulating factor 1 receptor.
Numbers that appear in parentheses represent the 95% conﬁdence interval.
* Statistically signiﬁcant.
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cyclin-dependent kinase inhibitor 2A (Cdkn2a), which encodes for
the p16INK4a cell cycle inhibitor and the p19Arf tumor suppressor, in
the pancreas due to Cre-mediated recombination. KIC mice null for
Gpc1 showed attenuated tumor growth, progression, and invasive-
ness, and decreased expression of pro-angiogenic genes compared
to KIC mice that were wild type for Gpc1 [82].
Another major contributor to the lack of eﬃcacy is the fact that
drug delivery in PDAC is impaired due to high interstitial pressures
and collapsed vessels [28]. It is possible that eﬃcacy could be im-
proved if anti-angiogenic therapywas administered simultaneously
with a stromal depleting agent known to increase perfusion. Out of
three recent pre-clinical studies that depleted various components
of the stroma, two resulted in improved perfusion [27,83,84], while
only one did not cause other untoward effects [28,85]. This was the
study that utilized recombinant hyaluronidase (PEGPH20) to deplete
the stroma, an agent now fast-tracked by the FDA to be used as an
investigative therapy in combination with gemcitabine and nab-
paclitaxel for the treatment of patients with metastatic pancreatic
cancer [28,85]. Initial Phase II results combining PEGPH20with nab-
paclitaxel/gemcitabinehave showna statistically signiﬁcant doubling
of the ORR, with a trend toward improved PFS and OS in patients
with high levels of hyaluronan [86]. Another strategy to promote
betterdrugdeliverywouldbe tonormalize thevasculaturevia stromal
remodeling instead of depletion [87], or via vascular promotion, a
Table 2
Phase III clinical trials using anti-angiogenic agents in PDAC.
Ref Phase Group Drug Experimental arm Active comparator arm Hazard ratio
Van Cutsem et al.
[60]
III Metastatic Bevacizumab (anti-
VEGF-A monoclonal
antibody)
• Bevacizumab + erlotinib +
gemcitabine
– ORR: 13.5% (9.8–17.9%)
– OS: 7.1 m (0–19.8 m)
– PFS: 4.6 m (0–18.3 m)
• Placebo + erlotinib +
gemcitabine
– ORR: 8.6% (5.6–12.4%)
– OS: 6 m (0.1–19.5 m)
– PFS: 3.6 m (0–13.6 m)
• OS HR 0.89 (0.74–1.07)
• PFS HR 0.73* (0.61–0.86)
Kindler et al. [61] III Advanced Bevacizumab (anti-
VEGF-A monoclonal
antibody)
• Bevacizumab + gemcitabine
– ORR: 13%
– OS: 5.8 m (4.9–6.6 m)
– PFS: 3.8 m (3.4–4 m)
• Placebo + gemcitabine
– ORR: 10%
– OS: 5.9 m (5.1–6.9 m)
– PFS: 2.9 m (2.4–3.7 m)
• OS HR 1.044 (0.88–1.24)
Kindler et al. [62] III Advanced Axitinib (SMI of
VEGFRs)
• Axitinib + gemcitabine
– ORR: 5% (2.5–8.3%)
– OS: 8.5 m (6.9–9.5 m)
– PFS: 4.4 m (4–5.6)
• Placebo + gemcitabine
– ORR: 2% (0.4–4%)
– OS: 8.3 m (6.9–10.3) m
– PFS: 4.4 m (3.7–5.2) m
• OS HR 1.014 (0.786–1.309)
• PFS HR 1.006 (0.779–1.298)
Gonçalves et al.
[63]
III Advanced Sorafenib (SMI of BRAF,
VEGFR-2, PDGFRB)
• Sorafenib + gemcitabine
– ORR: 23%
– OS: 8 m (6–10.8 m)
– PFS: 3.8 m (3.1–6 m)
• Placebo + gemcitabine
– ORR: 19%
– OS: 9.2 m (7.7–11.6 m)
– PFS: 5.7 m (3.7–7.5 m)
• OS HR 1.27 (0.837–1.932)
• PFS HR 1.04 (0.697–1.545)
Rougier et al. [64] III Advanced Ziv-Aﬂibercept
(recombinant fusion
protein that traps
VEGF-A, VEGF-B, PlGF)
• Ziv-aﬂibercept + gemcitabine
– 6 m survival: 54% (47–61%)
– OS: 6.5 m (5.6–7.9 m)
– PFS: 3.7 m (3.5–4.5 m)
• Placebo + gemcitabine
– 6 m survival: 63% (56–69%)
– OS: 7.8 m (6.8–8.6 m)
– PFS: 3.7 m (3.5–4.6 m)
• OS HR 1.165 (0.921–1.473)
• PFS HR 1.018 (0.828–1.253)
Yamaue et al. [65] III Advanced
or metastatic
Elpamotide (epitope
peptide of VEGFR-2)
• Elpamotide + gemcitabine
– OS: 8.36 m (7.46–10.18 m)
– PFS: 3.71 m (2.10–3.98 m)
• Placebo + gemcitabine
– OS: 8.54 m (7.33–10.84 m)
– PFS: 3.75 m (2.27–5.59 m)
• OS HR 0.87 (0.486–1.557)
Ref, reference; SMI, small molecule inhibitor; ORR, objective response rate; OS, overall survival; PFS, progression free survival; HR, hazard ratio; m, month(s); VEGF-A, vas-
cular endothelial growth factor A (gene: VEGFA); VEGFR, vascular endothelial growth factor receptor; BRAF, serine/threonine-protein kinase B-raf; VEGFR-2, vascular endothelial
growth factor receptor 2 (gene: KDR); PDGFRB, platelet-derived growth factor receptor beta; VEGF-B, vascular endothelial growth factor B (gene: VEGFB); PlGF, placenta
growth factor (gene: PGF).
Numbers that appear in parentheses represent the 95% conﬁdence interval.
* Statistically signiﬁcant.
Table 3
Phase II clinical trials using an anti-angiogenic agent + EGFR inhibitor in PDAC.
Ref Phase Group Drug Experimental arm Active comparator arm Hazard ratio
Ko et al. [75] II Metastatic Bevacizumab (anti-VEGF-A
monoclonal antibody)
• Bevacizumab + erlotinib
– ORR: 3%
– 6 m survival: 22%
– OS: 102 d (74–117 d)
– TTP: 40 d (35–41 d)
NA NA
Ko et al. [76] II Advanced Bevacizumab (anti-VEGF-A
monoclonal antibody)
• Bevacizumab + cetuximab
– ORR: 3.4% (0.1–17.8%)
– 6 m survival: 41.4% (23.7–58.3%)
– OS: 4.17 m (2.69–8.74)
– PFS: 1.91 m (1.81–2.76 m)
• Bevacizumab + cetuximab +
gemcitabine
– ORR: 13.8% (3.9–31.7%)
– 6 m survival: 39.3% (21.7–56.5%)
– OS: 5.41 m (3.84–6.74 m)
– PFS: 3.55 m (2–5.59 m)
NA
Watkins et al. [77] II Advanced Bevacizumab (anti-VEGF-A
monoclonal antibody)
• Bevacizumab + erlotinib +
capecitabine + gemcitabine
– ORR: 23% (11–38%)
– OS: 12.6 m
– PFS: 8.4 m
NA NA
Cardin et al. [78] II Advanced Sorafenib (SMI of BRAF,
VEGFR-2, PDGFRB)
• Sorafenib + erlotinib
– OS: 3.3 m or 99.5 d (71–188 d)
NA NA
Ref, reference; SMI, small molecule inhibitor; ORR, objective response rate; OS, overall survival; PFS, progression free survival; TTP, time to progression; HR, hazard ratio;
m, month(s); d, days(s); EGFR, epidermal growth factor receptor; VEGF-A, vascular endothelial growth factor A (gene: VEGFA); BRAF, serine/threonine-protein kinase B-raf;
VEGFR-2, vascular endothelial growth factor receptor 2 (gene: KDR); PDGFRB, platelet-derived growth factor receptor beta.
Numbers that appear in parentheses represent the 95% conﬁdence interval.
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mechanism which involves administering agents that enhance an-
giogenesis, ﬂow, and the leakiness of vessels [88].
Additionally, it has been shown that the tumor microenviron-
ment of transplantable models is not the same as that seen in a
genetically engineered mouse model (GEMM) [27]. In the trans-
plantable models, there is a lack of stroma and the pancreatic cancer
cells are close to the vessels [27]. For that reason, many cytotoxic
agents that were shown to be ineffective in human trials initially
showed eﬃcacy when tested in xenograft models [27,89]. Later, it
was found that such agents were just as ineffective when used in
GEMMs [27,89]. It is perhaps the same story with the anti-angiogenic
agents, as they were primarily only tested in subcutaneous or or-
thotopic nude mouse models of human PDAC. Future studies should
also utilize the increasing number of available GEMMs for PDAC
[90,91].
As is often observed in many clinical trials, patient responses are
variable, with only a subset of patients beneﬁting from the therapy,
while overall, no positive effect may be seen. It would be useful if
we could identify those patients who might beneﬁt the most via
the use of predictive biomarkers. Though some trials have at-
tempted to look for correlations between certain known pro-
angiogenic molecules circulating in the plasma and treatment
response, none have been successful to date [44,46,51,59]. With an
increasing number of studies utilizing high throughput technolo-
gies like RNA-Seq to proﬁle human tumors, it is possible that a gene
expression signature could be used. In fact, we have already iden-
tiﬁed such a signature by using TCGA RNA-Seq data [92–93].
Becausemost approved indications for bevacizumab involve con-
comitant administration with some form of cytotoxic chemotherapy,
at least one clinical study suggested that even if bevacizumab was
effective at normalizing the vasculature suﬃciently to improve drug
delivery, the fact still remains that we lack any effective chemo-
therapeutic or targeted agent for the treatment of PDAC [61].
In summary, future studies of angiogenesis in PDAC should con-
sider potential resistance mechanisms to targeted therapies, use
appropriate pre-clinical models that can recapitulate the microen-
vironment seen in human PDAC, and use biomarkers or gene
signatures to select patients for clinical trials.
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